drugset / Trial / NCT02427334

Dienogest Versus Luteal Phase Fluoxetine in the Management of Premenstrual Syndrome

NCT02427334

Phase 3 Unknown 210 enrolled Cairo University
RandomizedParallel-groupDouble-blindTreatment

Summary

Two hundreds and ten women with premenstrual syndrome will be randomly divided into 3 equal groups using computer generated random numbers. Group 1 will receive oral dienogest (visanne® Bayer, Germany) 2mg for 14 days starting from the 15th day of menstruation, Group 2 will receive fluoxetine (Prozac® Lilly, UK) 20mg and group 3 will receive an oral placebo foe 14 days starting from the 15th day of menstruation.

Timeline

Start
2015-04
Primary completion
2021-12
Completion
2021-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Dienogest Small molecule 2 mg Oral
Comparator Fluoxetine Small molecule 20 mg Oral

Indications